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Human in vivo models of systemic inflammation are used to study the physiological mechanisms of inflammation and
the effect of drugs and nutrition on the immune response. Although in vivo lipopolysaccharide (LPS) challenges have
been applied as methodological tool in clinical pharmacology studies, detailed information is desired on dose-response
relationships, especially regarding LPS hyporesponsiveness observed after low-dose in vivo LPS administration. A study
was performed to assess the in vivo inflammatory effects of low intravenous LPS doses, and to explore the duration of
the induced LPS hyporesponsiveness assessed by subsequent ex vivo LPS challenges.
This was a randomized, double-blind, placebo-controlled study with single ascending low doses of LPS (0.5, 1 and
2 ng/kg body weight) administered to healthy male volunteers (3 cohorts of 8 subjects, LPS:placebo 6:2). The in vivo
inflammatory response was assessed by measurement of cytokines and CRP. Ex vivo LPS challenges were performed
(at −2, 6, 12, 24, 48 and 72 hours relative to in vivo LPS administration) to estimate the duration and magnitude of LPS
hyporesponsiveness by assessment of cytokine release (TNF-α, IL-1β, IL-6, IL-8).
LPS administration dose-dependently increased body temperature (+1.5°C for 2 ng/kg LPS), heart rate (+28 bpm for
2 ng/kg LPS), CRP and circulating cytokines which showed clearly distinctive increases from placebo already at the
lowest LPS dose level tested (0.5 ng/kg, contrast for timeframe 0–6 hours: TNF-α +413%, IL-6 +288%, IL-8 +254%;
all p≤ 0.0001). In vivo LPS administration dose-dependently induced a period of hyporesponsiveness in the ex vivo
LPS-induced cytokine release (IL-1β, IL-6 and TNF-α), with maximal hyporesponsiveness observed at 6 hours, lasting no
longer than 12 hours. For IL-6 and IL-8, indications for immune cell priming were observed.
We demonstrated that an in vivo LPS challenge, with LPS doses as low as 0.5 ng/kg, elicits a cytokine response that is
clearly distinctive from baseline cytokine levels. This study expanded the knowledge about the dose-effect relationship of
LPS-induced hyporesponsiveness. As such, the low-dose LPS challenge has been demonstrated to be a feasible
methodological tool for future clinical studies exploring pharmacological or nutritional immune-modulating effects.
Keywords: Human endotoxemia model, Lipopolysaccharide, Hyporesponsiveness, Ex vivo LPS challenge, Cytokines,
C-Reactive Protein* Correspondence: mmoerland@chdr.nl
†Equal contributors
1Centre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The
Netherlands
Full list of author information is available at the end of the article
© 2014 Dillingh et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Dillingh et al. Journal of Inflammation 2014, 11:28 Page 2 of 9
http://www.journal-inflammation.com/content/11/1/28Introduction
Human models of systemic inflammation have been
developed with the purpose to explore the molecular
mechanisms and physiological significance of the sys-
temic inflammatory response encountered in acute as
well as chronic inflammatory conditions, such as sepsis,
trauma, type 2 diabetes, atherosclerosis, and Alzheimer’s
disease, in a controlled, standardized experimental setting.
A better understanding of the underlying molecular and
pathophysiological mechanisms could lead to optimized
prevention and treatment of these disorders, associated
with morbidity and mortality [1]. In addition, human
models of systemic inflammation can be applied in clin-
ical pharmacology studies to assess the effects of spe-
cific interventions (medicinal or non-medicinal) on the
inflammatory response in non-diseased populations.
Human endotoxemia is often used as a model of sys-
temic inflammation. In this experimental setting, purified
lipopolysaccharide (LPS, also referred to as endotoxin)
from the cell membrane of Escherichia coli (E. coli) or
other Gram-negative bacteria is administered intraven-
ously to healthy volunteers resulting in flu-like symptoms,
increased production of C-reactive protein (CRP) and in-
creased concentrations of pro- and anti-inflammatory cy-
tokines. Since the effects of E. coli are highly reproducible,
this is the predominant bacterial source used [1]. LPS in-
duces an inflammatory response via stimulation of Toll-
like receptors (TLRs), basic signaling receptors of the
innate immune system activated by tissue damage or by
molecules associated with pathogen-associated molecular
patterns (PAMPs) on invading microorganisms. LPS is
known to activate multiple intracellular pathways (e.g. the
MyD88-dependent and TRIF-dependent pathways) [2,3].
The human endotoxemia model has been studied exten-
sively and commonly applies relatively high LPS doses
(2–4 ng/kg body weight) [1,4-8]. However, an endotoxe-
mia model applying such relatively high LPS doses is not
preferred as methodological tool in clinical pharmacology
studies since the elicited immune response is so strong
that potential effects of immune-modulating interventions
may not be observed, other homeostatic mechanisms may
be temporarily impaired, and, importantly, the elicited im-
mune response at these LPS doses is not free of risk for
the volunteer. Studies applying lower LPS doses have been
performed [9,10], but thorough characterization of a hu-
man endotoxemia model at lower LPS dose levels is de-
sired. In the current study, 0.5 ng/kg was selected as the
lowest LPS dose to be administered intravenously because
an LPS dose of 0.2 ng/kg was shown previously to elicit no
cytokine response in vivo [11]. We performed a study to
characterize the LPS dose relationship of the human in-
flammatory response at low LPS doses (0.5, 1 and 2 ng/kg)
administered to healthy volunteers. Furthermore, we ex-
plored the effects of such an in vivo LPS challenge on theinflammatory response induced by subsequent ex vivo LPS
challenges. It has been described that an in vivo LPS chal-
lenge induces hyporesponsiveness to following in vivo or
ex vivo LPS challenges. The biochemical mechanisms ac-
counting for this hyporesponsiveness have been demon-
strated to involve negative regulators such as IRAK-M,
SOCS-1, SHIP, ST2 and IL-10 [2,3,12-18] and downregu-
lation of CD14 [19].
It has been reported that ex vivo LPS hyporesponsive-
ness following an in vivo LPS challenge was resolved after
1 week [4]. However, the exact time course of this
phenomenon and relation to LPS dose level is unclear.
Since such information could be important for (repeated)
application of in vivo and ex vivo LPS challenges in clinical
pharmacology studies, characterization of this hypore-
sponsiveness was an objective of our study.Methods
Subjects
Twenty-four healthy male volunteers, aged 18–28 years
(inclusive) with a BMI of 18 to 25 kg/m2 and a body
weight ≥ 56 kg, participated in this study. After providing
informed consent, subjects were medically screened within
3 weeks prior to participation. Exclusion criteria included
history of sepsis, cardiovascular disease, previous syncope
or malignancy, haemorrhagic diathesis, any active inflam-
matory or infectious disease, renal impairment, diabetes
mellitus, thyroid dysfunction, and prior exposure to endo-
toxin in an experimental setting within 4 weeks of the an-
ticipated exposure. Any use of medication that in the
opinion of the investigator would complicate or com-
promise the study or interfere with the study objectives
was not permitted during the study. The study was con-
ducted in accordance with the Declaration of Helsinki and
Guideline for Good Clinical Practice, and was approved by
the Medical Ethics Review Board of the Academic Medical
Center, Amsterdam, The Netherlands.Study design
This was a randomized, blinded, placebo controlled study
of ascending single doses of 0.5, 1 and 2 ng/kg LPS (U.S.
Reference Escherichia Coli (E. Coli) endotoxin CC-RE-Lot
3 (O113:H, 10:K negative, National Institute of Health,
Bethesda, MD, US, approximately 10 EU/ng); or placebo),
administered to healthy male subjects as an intravenous
bolus over 2 minutes. Each cohort included eight healthy
subjects, of which six subjects received LPS and two pla-
cebo (sodium chloride 0.9%). Subjects were prehydrated
with 1500 mL glucose/saline (2.5% glucose/0.45% sodium
chloride) 2 hours prior to LPS(/placebo) administration,
followed by an intravenous drip of 150 mL/hr for a period
of 6 hours. After LPS/placebo administration, subjects
were confined to the clinical research unit for 24 hours.
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Safety monitoring was performed by adverse events moni-
toring, physical examination, assessment of electrocar-
diogram (ECG) and vital signs, and laboratory evaluations
(routine hematology, chemistry, coagulation, and semi-
quantitative dipstick urinalysis). In case of clinically signifi-
cant findings in dipstick analysis, a microscopic investigation
of the urine was performed. For subject safety, maximally
two subjects were treated within one day, with a lag time
of at least 40 minutes between subjects. All blinded safety
data collected up to at least 24 hours after LPS/placebo
administration were reviewed before the decision was
made to escalate the LPS dose level and proceed with the
next cohort.
Inflammatory markers
The systemic inflammatory response was assessed by fre-
quent measurement of C-reactive protein (CRP) and a
panel of cytokines (IL-1β, IL-6, IL-8 and TNF-α) using a
human ultra-sensitive 4-plex (MSD). CRP levels were
measured as part of the standard chemistry panel. Samples
for cytokine analysis were collected in sodium heparin
(Greiner) tubes. In addition, the effect of an in vivo LPS
challenge on cytokine release (IL-1β, IL-6, IL-8, TNF-α)
induced by an ex vivo LPS challenge was studied. Blood
samples were collected in sodium heparin tubes (Greiner)
before and 6, 12, 24, 48 and 72 hours after the in vivo LPS
administration. Whole blood cultures were prepared with
a 1:1 dilution with RPMI 1640 medium and incubated
with LPS (E. Coli O111:B4, manufactured by Sigma-
Aldrich, Saint Louis, MO, US, catalog number L-3012, ap-
proximately 10 EU/ng) for 24 hours at 37°C, 5% CO2.
Cultures were centrifuged and supernatants were used for
cytokine assessment using the earlier mentioned cytokine
4-plex with a 20-fold dilution. Whole blood cultures were
performed by Good Biomarker Sciences, Leiden, The
Netherlands.
Statistical analysis
Statistical analysis was performed for circulating inflam-
matory markers and ex vivo-induced cytokines, which
were log-transformed prior to analysis. These repeatedly
measured parameters were analyzed with a mixed model
of variance with treatment, time, and treatment by time
as fixed factors and subject as random factor and the
baseline measurement as covariate. A variance compo-
nents (co)variance structure was used to model the
within-subject errors, the Kenward-Roger approximation
to estimate denominator degrees of freedom and the re-
stricted maximum likelihood method to estimate model
parameters. Contrasts were calculated within the model
for each parameter over the following time profiles:
baseline to 6 hours post-dose for circulating cytokines;
baseline to 24 hours post-dose for CRP; and at 6 hourspost-dose for ex vivo-induced cytokines. The general
treatment effect and specific contrasts were reported
with the estimated difference, the 95% confidence inter-
val (CI), the least square mean (LSM) estimates and the
p-value. Graphs of the LSMs estimates over time by
treatment present 95% confidence intervals as error bars
and change from baseline LSMs estimates. All analyses
were performed using SAS for Windows Version 9.1.3
(SAS Institute, Inc., Cary, NC, USA).
Results
Safety monitoring
Single intravenous low doses of LPS were well tolerated
in healthy male subjects. Observed adverse events (AEs)
were of mild severity and self-limiting without thera-
peutic intervention. The most frequent occurring AEs,
probably or possibly related to treatment, were head-
ache, observed in 66.7% of the LPS-treated subjects and
33.3% of the placebo-treated subjects and feeling cold,
observed in 44.4% of the LPS-treated subjects and none
of the placebo-treated subjects. No clinically relevant
changes or unexpected treatment-related trends were
observed in supine systolic and diastolic blood pressure,
body temperature, or ECG-derived parameters following
administration of LPS (Figure 1). LPS dose-dependently
increased body temperature and heart rate, with a max-
imal increase amounting approximately 1.5°C and 28 ±
13.2 bpm for the highest LPS dose tested, observed at
3–4 hours after LPS administration.
LPS administration resulted in a dose-dependent de-
crease in monocyte count (maximal change from base-
line −1.9 ± 2.3, −4.8 ± 3.6 and −7.7 ± 1.5% at 6 hours
post-LPS for doses of 0.5, 1 and 2 ng/kg, respectively),
returning to baseline levels within 12 to 24 hours post-
LPS (data not shown). In addition, LPS administration
resulted in decreased blood platelet count levels (min-
imal change from baseline of −15 ± 9.4, −28 ± 14.4,
and −31 ± 9.1*10^9/L at 4 hours post-dose, data not shown)
and an increase in neutrophil count (maximum change
from baseline 25.8 ± 3.5, 40.4 ± 9.5, and 42.9 ± 6.2% at
4 hours post-LPS for doses of 0.5, 1 and 2 ng/kg, re-
spectively) and leukocyte count (maximum change from
baseline 4.0 ± 1.3, 4.4 ± 1.2, 6.3 ± 1.4*10^9/L at 4–6
hours post-LPS), returning to baseline at 12–24 hours
post-dose (data not shown). Eosinophil, erythrocyte,
lymphocyte, and basophil counts and hematocrit and
hemoglobin slightly decreased after LPS administration,
with maximal changes observed 4 hours after LPS ad-
ministration (data not shown).
Activated partial thromboplastin time (APTT) was vari-
able over the day, ranging from −0.7 to +0.9 s around a
baseline concentration of 29.3 ± 1.8 s. LPS administration
resulted in a decrease in APTT, with an estimated differ-
ence of −2.0 s (p = 0.0151) at 1 ng/kg LPS and a maximal
Figure 1 Vital signs: temperature (°C, panel A), heart rate (bpm, panel B), systolic blood pressure (mmHg, panel C), diastolic blood
pressure (mmHg, panel D), change from baseline with standard deviation as error bars.
Figure 2 Activated Partial Thromboplastin Time (APTT) LSMs change from baseline profile, with 95% CI as error bars.
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(Figure 2). Although the decrease in APTT upon adminis-
tration of 2 ng/kg LPS was comparable in size, this differ-
ence did not reach a level of statistical significance (p =
0.1233). An effect of LPS administration on Prothrombin
Time (PT) was not observed (data not shown).
Circulating inflammatory markers
CRP levels were low in the placebo-treated group (data
not shown; baseline concentration 0.85 ± 1.08 mg/L, with
a minimal variability over time of maximally 0.30 ±
0.55 mg/L. LPS administration dose-dependently increased
CRP, maximal levels observed 24 hours post-dose (11.31 ±
6.73, 15.15 ± 3.93, and 18.42 ± 5.15 mg/L for LPS doses of
0.5, 1 and 2 ng/kg, respectively, Figure 3A; all contrasts
presented for the complete time profile up to 24 hours
post-dose, versus placebo, p < 0.0001). In the placebo-
treated group, circulating cytokine levels were minimal
(Figure 3B-D). LPS administration resulted in a dose-
dependent increase in TNF-α, IL-6, and IL-8, with max-
imal levels amounting 221.9 ± 61.2 pg/mL, 314.8 ± 130.9
and 329.4 ± 84.4 pg/mL, respectively. Maximal concentra-
tions were reached at 1.5–3 hours after LPS administra-
tion. For all LPS dose levels tested, contrasts for cytokineFigure 3 CRP (A) time profile graph, with standard deviation as error
with standard deviation as error bars.release versus placebo (time interval 0–6 hours post-dose)
reached a distinct level of significance (p < 0.0001). In a
considerable number of samples, IL-1β levels were below
the limit of quantification (LOQ, 0.6 pg/mL, data not
shown). In general, higher levels of IL-1β were observed
with increasing LPS doses. For all subjects in the 2 ng/kg
dose group, IL-1β levels above LOQ could be detected 3–
6 hours post-LPS, ranging from 0.7 to 2.6 pg/mL. No stat-
istical analysis was performed for IL-1β.
Ex-vivo LPS-induced cytokine release
Ex vivo LPS-induced IL-1β, IL-6, IL-8 and TNF-α re-
lease was variable over time, as observed in the placebo-
treated subjects (Figure 4). In vivo LPS administration
dose-dependently decreased ex vivo LPS-induced TNF-α
release at the highest two dose levels tested in the first
hours after the in vivo LPS challenge (Figure 4A). Max-
imal mean reduction was observed at 6 hours post-dose
with an estimated difference (95% CI) of −66.4% (−81.4
to −39.0%) and −74.7% (−86.0 to −54.3%) for 1 and
2 ng/kg, respectively, which differed significantly from
placebo (Table 1, p = 0.0005 and p < 0.0001 for 1 and
2 ng/kg, respectively). Subsequently, TNF-α release in-
creased and exceeded levels as observed for the placebobars; TNF-α (B), IL-6 (C), IL-8 (D) time profile graphs up to 6 hours,
Figure 4 TNF-α (A), IL-1β (B), IL-6 (C), IL-8 (D) after ex vivo LPS challenge (10 EU/ng, 24 hour incubation) LSMs change from baseline
profile, with 95% CI as error bars, in vivo LPS challenge on t = 0.
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release basically mirrored the patterns observed for TNF-
α release, with a maximal mean reduction at 6 hours post-
LPS with an estimated difference (95% CI) of −65.8%
(−79.5 to −43.1%) and −84.7% (−90.8 to −74.5%; Figure 4B
and Table 1; p < 0.0001 and p < 0.0001 versus placebo for
1 and 2 ng/kg, respectively), and a return to placebo levels
at approximately 12 hours post-dose. An in vivo LPS
challenge at 1 and 2 ng/kg significantly inhibited the
ex vivo LPS-induced release of IL-6 lasting for approxi-
mately 12 hours post-LPS and a maximal effect at 6 hours
with an estimated difference (95% CI) of −31.3% (−50.8
to −4.0%) and −41.3% (−58.1 to −17.8%; Figure 4C and
Table 1; p = 0.0283 and p = 0.0024 versus placebo for 1
and 2 ng/kg, respectively). Remarkably, ex vivo IL-6
release increased after the in vivo administration ofTable 1 Contrasts of ANCOVA at 6 hours post-dose after ex v
0.5 ng/kg vs placebo 1 ng/kg vs plac
Estimated difference (%) p-value Estimated diffe
TNF-α -13.6 0.6256 -66.4
IL-1β -30.0 0.1606 -65.8
IL-6 34.8 0.0754 -31.3
IL-8 55.1 0.0879 19.20.5 ng/kg LPS, peaking at 6 hours post-LPS and almost
significantly exceeding cytokine levels observed for
placebo-treated subjects with an estimated difference
(95% CI) of 34.8% (−3.1 to 87.5% (Figure 4C and Table 1;
p = 0.0754 versus placebo). A same response was ob-
served for ex vivo IL-8 release: in vivo administration of
LPS resulted in an increased IL-8 response to an ex vivo
LPS challenge for the two lowest LPS doses tested with
an estimated difference (95% CI) of 55.1% (−6.6 to
157.5%) and 19.2% (−28.8 to 99.5%) (Figure 4D and
Table 1; at 6 hours, p = 0.0879 and p = 0.4961 versus
placebo, for 0.5 and 1 ng/kg, respectively), but not for
the 2 ng/kg dose. The observed increases in IL-8 release
were followed by a strong decrease up to 12 hours post-
dose, which was consistent for all LPS doses tested
(Figure 4D).ivo LPS challenge
ebo 2 ng/kg vs placebo
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Human endotoxemia has been applied frequently as a con-
trolled and standardized model of systemic inflammation
providing mechanistic insight in molecular and physio-
logical inflammatory pathways. The in vivo LPS challenge
can also be applied as methodological tool in clinical
pharmacology studies to assess the effects of specific inter-
ventions (medicinal or non-medicinal) on the inflamma-
tory response in healthy volunteers. This experimental
model has been studied extensively, and commonly applies
relatively high LPS doses (2–4 ng/kg bodyweight) [1,4-8].
However, such relatively high LPS doses are not preferred
for reasons mentioned, and characterization of a human
endotoxemia model applying lower LPS dose levels is de-
sired. Therefore, we performed a study to characterize the
human inflammatory response induced by low LPS doses
administered to healthy volunteers. In addition, we ex-
plored the effects of an in vivo LPS challenge on the in-
flammatory response induced by subsequent ex vivo LPS
challenges. Although it is known from literature that
in vivo LPS challenge induces hyporesponsiveness to sub-
sequent in vivo or ex vivo LPS challenges [2,3,12-18], the
exact time course of this phenomenon and relation to LPS
dose level is unclear.
Administration of low LPS doses (0.5–2 ng/kg) to healthy
volunteers was well-tolerated and safe; all reported AEs
were of mild severity and self-limiting, and no unexpected
treatment-related trends in vital signs or ECG recordings
nor in urinary or blood laboratory parameters were mea-
sured. LPS administration dose-dependently increased body
temperature and heart rate with maximum levels observed
at 3–4 hours post-dose (change to baseline of approxi-
mately 1.5°C and 28 ± 13.2 bpm). Observed changes in
hematology parameters were expected as a result of LPS
treatment [5,8,20,21] and subject hydration from 2 hours
pre-dose till 6 hours post-dose. Furthermore, LPS adminis-
tration temporarily inhibited APTT, with a maximal de-
crease from baseline of approximately 3–4 s at 4 hours
post-LPS, in line with previously reported LPS effects on
coagulation [22,23]. There is a close interaction between
coagulation and inflammation pathways [24,25]. Stimula-
tion of monocytes with endotoxin results in an increased
expression of tissue factor, the main initiator of coagulation
[23,26,27]. Based on this observation an increase in PT
levels was expected via the extrinsic pathway, however,
this could not be confirmed by the results from our
study due to a high variability over the 24 hours time
profile. Cytokines such as IL-6 and TNF-α are the main
mediators of inflammation-induced coagulation [28,29].
Whereas changes in temperature and heart rate after an
in vivo LPS challenge could serve as a pharmacody-
namic readout measure for pharmacological or dietary
interventions, APTT effect size and contrast versus pla-
cebo of an in vivo LPS challenge were limited.In vivo LPS administration dose-dependently increased
circulating CRP and cytokine levels (TNF-α, IL-6 and
IL-8). Maximal CRP levels were observed 24 hours post-
LPS and maximal cytokine levels were observed 1.5–3
hours post-LPS. A single intravenous dose of LPS as low
as 0.5 ng/kg induced a distinct inflammatory response in
the healthy volunteers.
A power calculation was performed which showed that
in a parallel study design, at an LPS dose level of 0.5 ng/
kg, a sample size of 8 subjects per treatment group
would provide 80% power to detect an 28% inhibition in
the LPS-induced TNF-α response, at a two-sided signifi-
cance level of 0.05. Under the same conditions, it would
be possible to demonstrate an inhibition of the LPS-
induced cytokine response of 53% and 49% for IL-6 and
CRP, respectively. Given the fact that the inter subject
variability on log scale is well comparable between dif-
ferent LPS doses, this power calculation also applies for
LPS doses of 1 and 2 ng/kg.
Circulating IL-1β levels were low and for the majority of
the samples tested the level was below LOQ (0.6 pg/mL).
However, in the highest LPS dose group tested, an in-
crease in circulating IL-1β levels could be demonstrated at
3–6 hours post-LPS, with observed IL-1β levels ranging
from 0.7 to 2.6 pg/mL. This is in contrast with IL-1β re-
lease following an ex vivo LPS challenge of whole blood
cultures, which caused the release of substantial amounts
of IL-1β. Reports from other human endotoxemia experi-
ments also note IL-1β responses are very low or lacking,
despite high circulating levels of IL-6 and TNFα [30-35].
Interestingly, even in cases of severe sepsis, IL-1β can be
detected in only a small fraction of patients and corre-
sponds weakly with disease severity [36]. However it can
be acutely induced in response to certain surgical proce-
dures, and is implicated in many chronic inflammatory
conditions, such as diabetes, cardiovascular disease, and
rheumatoid arthritis. Since IL-1β expression is limited to
inflammasome activation and requires multiple signals
[37,38], this suggests that low-dose human endotoxemia
may be insufficient to induce systemic IL-1β. LPS
stimulation in whole blood cultures also induces cell
death, which may facilitate inflammasome activation
and induce substantial IL-1β release as seen in our
ex vivo LPS experiment.
In vivo LPS administration induced LPS hyporespon-
siveness as evidenced by ex vivo cytokine release of IL-
1β, IL-6 and TNF-α. This hyporesponsiveness was LPS
dose-dependent. Although the kinetics of endotoxin hy-
poresponsiveness have been described previously, the
exact time course of the hyporesponsiveness is not well
documented [4]. Here we demonstrate that LPS-induced
hyporesponsiveness of specific cytokines reached a max-
imum at 6 hours after the in vivo LPS challenge, and
lasted no longer than 12 hours. Interestingly, it has been
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sisted for at least 2 weeks [4]. This indicates that there is
a significant discrepancy between the LPS hyporespon-
siveness measured after an in vivo LPS challenge, for
which the tissue-resident macrophages, migrating leuko-
cytes and endothelial cells are implicated to be the main
sources of cytokine production, and an ex vivo LPS chal-
lenge, for which only the circulating leukocytes are the
source of cytokine release and there is no active clear-
ance of endotoxin since the system is closed [4,39]. The
fact that the estimated duration of the derangement of
the immune system induced by an in vivo LPS challenge
is dependent on the selected methodology (assessment
by ex vivo LPS challenge or in vivo LPS challenge)
should be carefully taken into account when designing
future clinical pharmacology studies applying in vivo/
ex vivo LPS challenges, and this process should be
driven by the nature and mechanism of action of the in-
vestigational product.
Interestingly, patterns for ex vivo LPS-induced IL-8 re-
lease (at all in vivo LPS doses tested) and IL-6 release (at
the lowest in vivo LPS dose tested) differed from the pat-
terns observed for IL-1β and TNF-α: a preceding in vivo
LPS challenge caused an increased cytokine release after an
ex vivo LPS challenge, rather than an inhibition of cytokine
release. It may be well possible that immune cells were
primed by the low-dose in vivo LPS challenge, resulting in
an augmented IL-8 and IL-6 responses after ex vivo LPS
stimulation. Priming of innate immune cells by low endo-
toxin levels has been described before, and allows the im-
mune system to elicit a strong inflammatory response
against potential pathogens [2]. Although priming of the
murine immune system has been explored rather exten-
sively, the underlying mechanisms in human immunology
are poorly understood. Pretreatment of murine macrophage
cells with very low doses of LPS results in an augmented
cytokine production after subsequent LPS stimulation,
which is LPS concentration-dependent [40-42]. In general
it should be noted that humans are much more sensitive to
LPS than mice, indicating the relative poor feasibility of
murine models to support human endotoxin responses
[43]. The fact that, dependent on the in vivo LPS dose ap-
plied and specific cytokine measured, either LPS hypore-
sponsiveness or LPS priming is observed in a relatively
narrow LPS dose range (0.5–2 ng/kg) indicates that a deli-
cate balance exists between endotoxin hyporesponsiveness
and endotoxin priming, which is still to be characterized in
more detail.
It should be noted that sample collection tubes used for
ex vivo LPS challenges contained an endotoxin-like con-
tamination. Although the exact level of contamination
could not be expressed in relative endotoxin units, add-
itional experiments indicated that the contamination was
TLR4-specific. As a consequence of this contamination,ex vivo LPS challenges were performed at an endotoxin
level resulting in a maximal TLR4-mediated response
(EC100) rather than the anticipated sub-maximal response
level (EC80), which was believed not to affect study
outcomes.
Conclusion
Overall, our experiments demonstrate that human endo-
toxemia induced by commonly applied relatively high
LPS doses (exceeding 2 ng/kg) can be avoided: applica-
tion of LPS doses as low as 0.5 ng/kg result in significant
responses in routine safety markers (e.g. temperature,
blood pressure and heart rate) and circulating cytokine
levels that can function as pharmacodynamic markers.
As such, the low-dose LPS challenge has been demon-
strated to be a feasible methodological tool for future
clinical studies exploring pharmacological or nutritional
immune-modulating effects. An in vivo LPS challenge
induced immune cell hyporesponsiveness or immune
cell priming (dependent on in vivo LPS dose and cyto-
kine readout), determined by repeated ex vivo LPS chal-
lenges, but the duration of these effects was limited.
These results indicate that a combination of in vivo LPS
administration and repeated ex vivo LPS challenges can
be applied in clinical pharmacology studies.
Abbreviations
AE: Adverse Event; APTT: Activated Partial Thromboplastin Time; BMI: Body Mass
Index; bpm: beats per minute; CD14: Cluster of differentiation 14; CI: Confidence
Interval; CRP: C-Reactive Protein; ECG: Electrocardiogram; E. Coli: Escherichia Coli;
IL-1β: Interleukin-1β; IL-6: Interleukin-6; IL-8: Interleukin-8; IL-10: Interleukin-10;
IRAK-M: Interleukin-1 receptor-associated kinase-M; LPS: Lipopolysaccharide;
LOQ: Limit Of Quantification; LSMs: Least Square Means; PAMP: Pathogen-
associated molecular patterns; PT: Prothrombin Time; SHIP: SH2 domain-
containing inositol 5′-phosphatase; SOCS-1: Suppressor of Cytokine Signaling-1;
TLR: Toll-like receptor; TNF-α: Tumor Necrosis Factor-α; TRIF: TIR domain-
containing adapter inducing IFN-β.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MM and KB conceptualized the study and supervised the complete study.
MRD, EPP, MM and KB designed the study, KEM was involved in the design of the
laboratory methods and carried out the laboratory experiments. MRD, EPP, MM
and KB were responsible for the clinical execution of the study and interpretation
of the results. All authors were involved in writing the manuscript and approved
the final manuscript.
Author details
1Centre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The
Netherlands. 2Good Biomarker Sciences, Zernikedreef 8, 2333 CL, Leiden, The
Netherlands. 3Academic Medical Center, Meibergdreef 9, 1105 AZ,
Amsterdam, The Netherlands.
Received: 27 February 2014 Accepted: 27 August 2014
References
1. Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Moller K:
Human endotoxemia as a model of systemic inflammation. Curr Med Chem
2008, 15:1697–1705.
Dillingh et al. Journal of Inflammation 2014, 11:28 Page 9 of 9
http://www.journal-inflammation.com/content/11/1/282. Fu Y, Glaros T, Zhu M, Wang P, Wu Z, Tyson JJ, Li L, Xing J: Network topologies
and dynamics leading to endotoxin tolerance and priming in innate immune
cells. PLoS Comput Biol 2012, 8:e1002526.
3. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H:Molecular
mechanisms of macrophage activation and deactivation by lipopolysaccharide:
roles of the receptor complex. Pharmacol Ther 2003, 100:171–194.
4. Kox M, De Kleijn KS, Pompe JC, Ramakers BP, Netea MG, Van der Hoeven JG,
Hoedemaekers CW, Pickkers P: Differential ex vivo and in vivo endotoxin
tolerance kinetics following human endotoxemia. Crit Care Med 2011,
39:1866–1870.
5. Draisma A, Pickkers P, Bouw MP, van der Hoeven JG: Development of
endotoxin tolerance in humans in vivo. Crit Care Med 2009, 37:1261–1267.
6. van der Poll T, Coyle SM, Moldawer LL, Lowry SF: Changes in endotoxin-
induced cytokine production by whole blood after in vivo exposure of
normal humans to endotoxin. J Infect Dis 1996, 174:1356–1360.
7. de Vos AF, Pater JM, Van den Pangaart PS, De Kruif MD, Van 't Veer C, Van der
Poll T: In vivo lipopolysaccharide exposure of human blood leukocytes
induces cross-tolerance to multiple TLR ligands. J Immunol 2009, 183:533–542.
8. Van Eijk LT, Van der Pluijm RW, Ramakers BP, Dorresteijn MJ, Van der Hoeven JG,
Kox M, Pickkers P: Body mass index is not associated with cytokine induction
during experimental human endotoxemia. Innate Immun 2013, 20:61–67.
9. Ferguson JF, Mulvey CK, Patel PN, Shah RY, Doveikis J, Zhang W, Tabita-Martinez J,
Terembula K, Eiden M, Koulman A, Griffin JL, Mehta NN, Shah R, Propert KJ,
Song WL, Reilly MP: Omega-3 PUFA supplementation and the response to
evoked endotoxemia in healthy volunteers. Mol Nutr Food Res 2013, 58:601–613.
10. Nieuwdorp M, Meuwese MC, Mooij HL, van Lieshout MH, Hayden A, Levi M,
Meijers JC, Ince C, Kastelein JJ, Vink H, Stroes ES: Tumor necrosis factor-alpha
inhibition protects against endotoxin-induced endothelial glycocalyx
perturbation. Atherosclerosis 2009, 202:296–303.
11. Draisma A, De Goeij M, Wouters CW, Riksen NP, Oyen WJ, Rongen GA,
Boerman OC, van Deuren M, van der Hoeven JG, Pickkers P: Endotoxin
tolerance does not limit mild ischemia-reperfusion injury in humans
in vivo. Innate Immun 2009, 15:360–367.
12. Morris M, Li L: Molecular mechanisms and pathological consequences of
endotoxin tolerance and priming. Arch Immunol Ther Exp (Warsz) 2012, 60:13–18.
13. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA:
IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002,
110:191–202.
14. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G: LPS-induced upregulation
of SHIP is essential for endotoxin tolerance. Immunity 2004, 21:227–239.
15. Chang J, Kunkel SL, Chang CH: Negative regulation of MyD88-dependent
signaling by IL-10 in dendritic cells. Proc Natl Acad Sci USA 2009,
106:18327–18332.
16. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O’Neill LA, Liew FY: ST2 is an
inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and
maintains endotoxin tolerance. Nat Immunol 2004, 5:373–379.
17. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, Seki E, Sato S,
Takeuchi O, Takeda K, Akira S, Yamanishi K, Kawase I, Nakanishi K, Kishimoto T:
SOCS-1 participates in negative regulation of LPS responses. Immunity 2002,
17:677–687.
18. Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, Yoshida H, Kubo M,
Yoshimura A: SOCS1/JAB is a negative regulator of LPS-induced macrophage
activation. Immunity 2002, 17:583–591.
19. Schaaf B, Luitjens K, Goldmann T, van Bremen T, Sayk F, Dodt C, Dalhoff K,
Droemann D: Mortality in human sepsis is associated with downregulation
of Toll-like receptor 2 and CD14 expression on blood monocytes. Diagn
Pathol 2009, 4:12.
20. Van 't Veer C, Van den Pangaart PS, Van Zoelen MA, De Kruif M, Birjmohun RS,
Stroes ES, de Vos AF, Van der Poll T: Induction of IRAK-M is associated with
lipopolysaccharide tolerance in a human endotoxemia model. J Immunol
2007, 179:7110–7120.
21. Sivapalaratnam S, Farrugia R, Nieuwdorp M, Langford CF, van Beem RT,
Maiwald S, Zwaginga JJ, Gusnanto A, Watkins NA, Trip MD, Ouwehand WH:
Identification of candidate genes linking systemic inflammation to
atherosclerosis; results of a human in vivo LPS infusion study. BMC Med
Genomics 2011, 4:64.
22. Ungerstedt JS, Soop A, Sollevi A, Blomback M: Bedside monitoring of
coagulation activation after challenging healthy volunteers with intravenous
endotoxin. Thromb Res 2003, 111:329–334.
23. De Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J,
Levi M, Van Deventer SJ, Van der Poll T: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the
fibrinolytic and cytokine response during human endotoxemia. Blood 2000,
95:1124–1129.
24. Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation
and coagulation. Circulation 2004, 109:2698–2704.
25. Esmon CT: The interactions between inflammation and coagulation.
Br J Haematol 2005, 131:417–430.
26. Levi M, van der Poll T, Ten Cate H: Tissue factor in infection and severe
inflammation. Semin Thromb Hemost 2006, 32:33–39.
27. Franco RF, De Jonge E, Dekkers PE, Timmerman JJ, Spek CA, Van Deventer SJ,
Van Deursen P, Van Kerkhoff L, Van Gemen B, Ten Cate H, Reitsma PH:
The in vivo kinetics of tissue factor messenger RNA expression during
human endotoxemia: relationship with activation of coagulation. Blood
2000, 96:554–559.
28. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der
Poll T: Interleukin-6 stimulates coagulation, not fibrinolysis, in humans.
Thromb Haemost 1996, 76:738–742.
29. van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ,
Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW: Activation of coagulation
after administration of tumor necrosis factor to normal subjects. N Engl J
Med 1990, 322:1622–1627.
30. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A:
Experimental endotoxemia in humans: analysis of cytokine release and
coagulation, fibrinolytic, and complement pathways. Blood 1990,
76:2520–2526.
31. van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P:
Gender differences in the innate immune response and vascular reactivity
following the administration of endotoxin to human volunteers. Crit Care
Med 2007, 35:1464–1469.
32. Coyle SM, Calvano SE, Lowry SF: Gender influences in vivo human responses
to endotoxin. Shock 2006, 26:538–543.
33. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello CA,
Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis
factor after endotoxin administration. N Engl J Med 1988, 318:1481–1486.
34. Van Zee KJ, Coyle SM, Calvano SE, Oldenburg HS, Stiles DM, Pribble J,
Catalano M, Moldawer LL, Lowry SF: Influence of IL-1 receptor blockade
on the human response to endotoxemia. J Immunol 1995, 154:1499–1507.
35. Dorresteijn MJ, van Eijk LT, Netea MG, Smits P, van der Hoeven JG, Pickkers P:
Iso-osmolar prehydration shifts the cytokine response towards a more anti-
inflammatory balance in human endotoxemia. J Endotoxin Res 2005,
11:287–293.
36. Blackwell TS, Christman JW: Sepsis and cytokines: current status. Br J Anaesth
1996, 77:110–117.
37. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH,
van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ,
Kullberg BJ, Rubartelli A, Van der Meer JW, Dinarello CA: Differential
requirement for the activation of the inflammasome for processing
and release of IL-1beta in monocytes and macrophages. Blood 2009,
113:2324–2335.
38. Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform
triggering activation of inflammatory caspases and processing of proIL-
beta. Mol Cell 2002, 10:417–426.
39. Dorresteijn MJ, Draisma A, van der Hoeven JG, Pickkers P:
Lipopolysaccharide-stimulated whole blood cytokine production does
not predict the inflammatory response in human endotoxemia. Innate
Immun 2010, 16:248–253.
40. West MA, Koons A: Endotoxin tolerance in sepsis: concentration-
dependent augmentation or inhibition of LPS-stimulated macrophage
TNF secretion by LPS pretreatment. J Trauma 2008, 65:893–898.
41. Hirohashi N, Morrison DC: Low-dose lipopolysaccharide (LPS) pretreatment
of mouse macrophages modulates LPS-dependent interleukin-6
production in vitro. Infect Immun 1996, 64:1011–1015.
42. Deng H, Maitra U, Morris M, Li L: Molecular mechanism responsible for
the priming of macrophage activation. J Biol Chem 2013, 288:3897–3906.
43. Munford RS: Murine responses to endotoxin: another dirty little secret?
J Infect Dis 2010, 201:175–177.
doi:10.1186/s12950-014-0028-1
Cite this article as: Dillingh et al.: Characterization of inflammation and
immune cell modulation induced by low-dose LPS administration to
healthy volunteers. Journal of Inflammation 2014 11:28.
